CMS to increase reimbursement for new sickle cell gene therapies
The Centers for Medicare and Medicaid Services (CMS) said Wednesday that it will increase reimbursements for two newly approved sickle cell gene therapies that could potentially reverse the debilitating effects of the disease.
CMS typically reimburses 65% of the cost of a new technology, but will increase that to 75% for Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy, as well as for bluebird bio’s Lyfgenia, according to a proposed rule. The change will take effect in the US government’s 2025 fiscal year and conclude at the end of the two- to three-year so-called “newness” period.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
